InterCure

Non Invasive Medical Device for Hypertension Treatment.

Launch date

1994

Employees

Market cap

Enterprise valuation

$125m (Public information from Sep 2024)

Rishon LeTsiyon Center District (HQ)

http://www.resperate.com/

https://twitter.com/resperate https://www.linkedin.com/company/132572/https://apps.apple.com/app/id1432429758 https://play.google.com/store/apps/details?id=com.twobreathe.soft2breathe

Revenues, earnings & profits over time

ILS	2018	2019	2020	2021	2022	2023	2024
Revenues	-	8.9m	65.0m	220m	389m	391m	1.3b
% growth	-	-	629 %	238 %	77 %	1 %	235 %
EBITDA	-	(21.2m)	1.8m	37.6m	64.5m	46.6m	(31.3m)
% EBITDA margin	-	(238 %)	3 %	17 %	17 %	12 %	(2 %)
Profit	-	(3.0m)	(37.2m)	4.7m	44.8m	(62.0m)	(70.4m)
% profit margin	-	(34 %)	(57 %)	2 %	12 %	(16 %)	(5 %)
EV / revenue	-	44.1x	6.3x	3.8x	1.5x	0.8x	0.1x
EV / EBITDA	-	-18.6x	225.8x	22.5x	8.9x	6.6x	-1.9x
R&D budget	-	1.7m	1.6m	1.2m	<1m	<1m	-
R&D % of revenue	-	19 %	2 %	1 %	-	-	-

Date	Investors	Amount	Round
Oct 2011	N/A	N/A	IPO
Nov 2018*	Adam Neumann	$5.0m	Post IPO Equity
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

Fore Biotherapeutics